China SXT Pharmaceuticals, Inc. (SXTC) Total liabilities 2018–2026
China SXT Pharmaceuticals, Inc. (SXTC) total liabilities at each fiscal year-end, per SEC filings.
$5.0MFY2026 · since FY2018: $4.4M → $5.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $5.0M | -18.9% |
| FY2025 | $6.2M | -32.3% |
| FY2024 | $9.2M | -38.1% |
| FY2023 | $14.9M | -13.2% |
| FY2022 | $17.1M | -7.9% |
| FY2021 | $18.6M | +51.1% |
| FY2020 | $12.3M | +93.3% |
| FY2019 | $6.4M | +45.5% |
| FY2018 | $4.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net incomeSXTC Net marginSXTC Gross profitSXTC Gross marginSXTC Operating incomeSXTC Operating marginSXTC Operating cash flowSXTC Free cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Shareholders’ equitySXTC overview →